| Aetna | Certolizumab Pegol (Cimzia) | 2026-07-01 |
| UHC UMR Medical and Drug | Beds and Mattresses – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Carrier Testing Panels for Genetic Diseases – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Category III Codes – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Cell-Free Fetal DNA Testing – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Chelation Therapy – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Cognitive Rehabilitation and Coma Stimulation – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Denosumab – Commercial Medical Benefit Drug Policy | 2026-07-01 |
| UHC UMR Medical and Drug | FDA Cleared or Approved Companion Diagnostic Testing – Commercial and Individual Exchange Medical Policy | 2026-07-01 |
| UHC UMR Medical and Drug | Gender Dysphoria Treatment – Commercial and Individual Exchange Medical Policy | 2026-07-01 |